·SEC EDGARLow
Prieur Marc sold $284K of ATR
Prieur Marc (Segment President) sold 2,000 shares of APTARGROUP, INC. (ATR) at $141.99 ($0.28M total) on 2026-11-02.
StockNYSE · US · USDHealthcare · Medical Instruments & Supplies
$ATR
APTARGROUP, INC.
Aptar designs and manufactures dosing, dispensing and protection technologies for pharmaceutical and consumer product customers. Its products include dispensing pumps, closures, aerosol valves, elastomeric packaging components, active material science solutions and digital health products and services. Aptar is headquartered in Crystal Lake, Illinois and has approximately 14,000 employees in approximately 20 different countries. Aptar operates three segments. Pharma serves prescription drug, consumer health care, injectables, active material science and digital health markets, providing drug delivery systems, pharmaceutical packaging and related services. Beauty sells pumps, airless systems and valves for fragrance, skincare, cosmetics, personal care and home care. Closures sells dispensing closures, sealing solutions and food service trays for food, beverage and other markets. Aptar makes money by selling these products and services to customers across these markets.
AlphAI earnings readThird Quarter 2026 · OCT 29Aptar reported third-quarter sales growth across all three segments, while Russian subsidiary deconsolidation reduced reported earnings and adjusted EBITDA margins declined year over year.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $ATRvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ATR in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $284K 1 txs
Prieur Marc1× · $284K
10b5-1 share of filings0%
Top stories · $ATRMore →
·investing.com
Aptar Q3 2026 slides: broad growth, strong Pharma pipeline
AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.
·investing.com
AptarGroup earnings beat by $0.05, revenue topped estimates
AptarGroup (NYSE: ATR) reported Q3 EPS of $1.52, beating estimates by $0.05, with revenue at $1.02B, above consensus. Q4 2026 EPS guidance is $1.39-$1.47. Stock is down 2.48% in 3 months but up 5.05% in 12 months. InvestingPro rates its financial health as good.
ATR sentiment & insider activity
Recent ATR coverage spans earnings, financial news and insider activity.
In the last 30 days, ATR insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($284K). The most active reporter was Prieur Marc, Segment President, with 1 filing.
What's driving ATR
The insider sale may signal modest concern and could exert slight downward pressure on the stock.
Earnings beat and upbeat guidance drive short‑term upside.
Beat on both EPS and revenue, with Q4 EPS guidance slightly above consensus, likely supporting near-term sentiment.
Guidance and segment momentum likely support the stock, but margin pressure and the Russian deconsolidation loss are key offsets.
Dividend increase signals continued capital return and confidence, but it is unlikely to drive a large repricing versus broader fundamentals.
AlphAI scores every news story that mentions ATR with an AI model for sentiment and relevance, and aggregates insider trades from APTARGROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ATR
Score
Prieur Marc sold $284K of ATR
Prieur Marc (Segment President) sold 2,000 shares of APTARGROUP, INC. (ATR) at $141.99 ($0.28M total) on 2026-11-02.
Aptar Q3 2026 slides: broad growth, strong Pharma pipeline
AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.
AptarGroup earnings beat by $0.05, revenue topped estimates
AptarGroup (NYSE: ATR) reported Q3 EPS of $1.52, beating estimates by $0.05, with revenue at $1.02B, above consensus. Q4 2026 EPS guidance is $1.39-$1.47. Stock is down 2.48% in 3 months but up 5.05% in 12 months. InvestingPro rates its financial health as good.
APTARGROUP, INC. (ATR): Aptar Reports Third Quarter 2026 Results
APTARGROUP, INC. (ATR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aptar Reports Third Quarter 2026 Results Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results
AptarGroup raises quarterly dividend 4% to $0.50 per share
AptarGroup (NYSE:ATR) raised its quarterly dividend by 4% to $0.50 per share, payable December 3, 2026. This marks 33 years of consecutive annual dividend increases, reflecting the company's confidence in future growth. ATR manufactures drug delivery and consumer product dispensing systems.
Aptar Pharma enters collaboration with Stevanato Group
Aptar Pharma (ATR) and Stevanato Group (STVN) are collaborating to evaluate pre-filled syringe configurations for biotech and pharmaceutical companies. They aim to provide system-level data to support earlier evaluation of packaging configurations, focusing on sensitive biologics and injectable therapies. The collaboration combines Aptar Pharma's expertise in elastomeric components with Stevanato Group's expertise in prefillable syringe systems.
Aptar Pharma acquires Pulmotree to expand inhaler portfolio
Aptar Pharma, part of AptarGroup (NYSE:ATR), acquired Pulmotree, a Munich-based life science company specializing in pulmonary drug delivery systems. The acquisition adds Pulmotree's Kolibri Non-Propellant Liquid Inhaler platform to Aptar Pharma's portfolio. Financial terms were not disclosed. ATR employs 14,000 people across 20 countries.
AptarGroup names Virginie Maes president of pharma unit
AptarGroup Inc. (NYSE: ATR) appointed Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes joins from Amcor, where she led global pharma and medical packaging. She has prior experience at McKinsey, Terra Firma, and Morgan Stanley. ATR is a provider of drug delivery and consumer product dispensing technologies.
Aptar Pharma receives CE mark for intranasal vaccine device
AptarGroup (NYSE:ATR) announced its LuerVax intranasal vaccine device and Spray Divider received CE marking, meeting EU safety and performance standards. The devices are for vaccine administration and support development programs. ATR is a global developer of drug delivery technologies.
UBS Initiates Coverage on AptarGroup With Neutral Rating, $135 Price Target
UBS initiated coverage on AptarGroup with a neutral rating and a $135 price target. The company's stock is currently trading at $121.81. Recent events include management changes and a presentation at the Wells Fargo Healthcare Conference.